Aron Gyorgypal

Aron Gyorgypal
Harvard Medical School | HMS

Doctor of Philosophy

About

10
Publications
754
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
28
Citations
Citations since 2017
10 Research Items
28 Citations
2017201820192020202120222023051015
2017201820192020202120222023051015
2017201820192020202120222023051015
2017201820192020202120222023051015
Introduction
Ambitious, performance-driven, and goal-oriented biochemical engineer with an unparalleled work ethic and passion to learn.
Additional affiliations
June 2023 - present
Massachusetts General Hospital
Position
  • Post-Doctoral Fellow
August 2018 - May 2023
Rutgers, The State University of New Jersey
Position
  • Graduate Research Associate
Education
August 2018 - May 2023
Rutgers, The State University of New Jersey
Field of study
  • Chemical and Biochemical Engineering
August 2015 - August 2018
New Jersey Institute of Technology
Field of study
  • Chemical Engineering

Publications

Publications (10)
Article
Full-text available
Continuous bioprocessing is significantly changing the biological drugs or biologics manufacturing landscape by potentially improving product quality, process stability and/or overall profitability, as similarly seen during adoption of advanced manufacturing processes for small molecule drugs in the past decade. However, implementation of continuou...
Preprint
With the transition toward continuous bioprocessing, process analytical technology (PAT) is becoming necessary for rapid and reliable in-process monitoring during biotherapeutics manufacturing. Bioprocess 4.0 is looking to build an end-to-end bioprocesses that includes PAT-enabled real-time process control. This is especially important for drug pro...
Preprint
Full-text available
Monoclonal antibodies (mAbs) represent a majority of biotherapeutics on the market today. These glycoproteins undergo post-translational modifications, such as N-linked glycosylation, that influence the structural & functional characteristics of the antibody. Glycosylation is a heterogenous post-translational modification that may influence therape...
Article
N-glycosylation is a post-translational modification that occurs during the production of monoclonal antibody (mAb) therapeutics. During production of mAb based therapeutics the use of various hosts and cell culture additives attribute to glycan heterogeneity. The safety and efficacy of monoclonal antibodies with mechanism of actions that utilize F...
Article
With the transition toward continuous bioprocessing, Process Analytical Technology (PAT) is becoming necessary for rapid and reliable in-process monitoring during biotherapeutics manufacturing. Bioprocess 4.0 is looking to build end-to-end bioprocesses...
Preprint
Full-text available
Post-translational modification such as N-Glycosylation on biologics during the production of monoclonal antibody (mAb) based therapeutics is a critical quality attribute that dictates safety and efficacy. Variability is introduced in the cell culture process which influences, the glycosylation pattern which is known to be highly heterogenous and m...
Preprint
The biopharmaceutical industry is transitioning towards adoption of continuous biomanufacturing practices that are often more flexible and efficient than traditional batch processes. Regulatory agencies such as the Food and Drug Administration (FDA) are further urging use of advanced PAT to analyze the design space to increase process knowledge and...

Network

Cited By